Tai Sandi See is Chief Development Officer at Lexeo Therapeutics, Inc. (LXEO). They have made 5 open-market trades across 1 company since 2025, most recently 2025-11-18.
CIK 0002009350
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 5 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| LXEO | 65,476 | $173K |
Shares reported on the most recent Form 4, priced at the 2025-11-20 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| LXEO | SELL | 2025-11-18 | 2025-11-20 | $9.27 | $4K | -2.1% | +20.1% | -28.9% |
| LXEO | SELL | 2025-10-17 | 2025-10-17 | $8.95 | $35K | +2.4% | -2.1% | -22.5% |
| LXEO | SELL | 2025-08-18 | 2025-08-20 | $4.67 | $2K | +1.1% | +8.6% | +93.7% |
| LXEO | SELL | 2025-05-16 | 2025-05-20 | $2.77 | $1K | -19.8% | +15.3% | +45.1% |
| LXEO | SELL | 2025-02-19 | 2025-02-21 | $4.41 | $7K | -30.7% | +4.6% | -21.2% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.